Feasibility Study to Collect and Assess Safety Data for a Radiofrequency Microneedling Device for Electrocoagulation and Hemostasis of Soft Tissues for Dermatologic Conditions
Launched by CYNOSURE, INC. · Aug 3, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new device called the Potenza, which uses a technique called radiofrequency microneedling to improve various skin conditions like wrinkles, fine lines, acne scars, and loose skin. The main goal of this study is to collect information about the safety and effectiveness of this device for treating these dermatologic issues. The trial is currently looking for participants, particularly healthy men and women aged 22 to 65 who have specific skin types and can commit to attending all scheduled visits without undergoing other treatments in the area being studied.
If you decide to participate, you will undergo treatments with the Potenza device and will be monitored throughout the study to ensure your safety. It's important to note that certain individuals, such as those who are pregnant, have certain medical devices or conditions, or have specific allergies, may not be eligible to participate. This study aims to gather valuable data that could help improve skin treatment options in the future. If you're curious about the trial or think you might qualify, it could be a great opportunity to contribute to advancements in dermatologic care.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A healthy, non-smoking male or female between the age of 22-65 years old.
- • Fitzpatrick skin type I to VI.
- • Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
- • Understands and accepts the obligation and is logistically able to be present for all visits.
- • Is willing to comply with all requirements of the study and sign the informed consent document.
- Exclusion Criteria:
- • Is pregnant or of childbearing potential and not using medically effective birth control, or has been pregnant in the last 3 months, currently breast feeding or planning a pregnancy during the study.
- • The subject is currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within in the area to be treated 1 month prior to entering this study.
- • The subject has a pacemaker.
- • The subject had previous use of gold thread skin rejuvenation.
- • The subject has a cut, wound, or infected skin on the area to be treated (but skin eruptions may be treated).
- • The subject has a metal implant that interferes with the transmission of energy to the electrical field.
- • The subject has any embedded electronic devices that give or receive a signal.
- • The subject has Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant.
- • The subject is allergic to adhesives such as glues on medical tape: they should be alerted that a rash may occur on the neutral electronic monitoring pad (NEM or neutral pad) site, and an over-the-counter preparation may be used to treat the area.
- • The subject is allergic to gold.
- • The subject has an unrealistic expectation of the results: this is not plastic surgery, and all subjects should be fully informed of the treatment's expected results.
- • The subject has nerve insensitivity to heat in the treatment area or in the neutral pad placement area.
- • The subject has severe laxity or sagging that causes redundant folds of tissue or hanging skin in the area to be treated: this treatment will be ineffective.
- • The subject has used Accutane (isotretinoin) six to twelve months prior to treatment, as this can thin the skin and make it brittle.
- • The subject is taking aspirin or are currently taking antiplatelets, thrombolytics, anti- inflammatories or anticoagulants.
- • The subject has a history of bleeding coagulopathies.
- • The subject is allergic to topical anesthetic.
- * The subject has any of the following conditions:
- • Diabetes
- • Epilepsy
- • Autoimmune disease
- • Herpes simplex
- • HIV
- • Hypertension
- • Dermatitis
- • The subject has keloid formation propensity.
- • Subjects with electronic implants such as cardiac defibrillator. It may interfere with operation of electronic implants or damage the implants, causing risks.
- • The subject has any condition or is in a situation which in the investigator's opinion may put the subject at significant risk, may confound study results or may interfere.
- • significantly with the subject's participation.
About Cynosure, Inc.
Cynosure, Inc. is a leading medical device company specializing in innovative aesthetic and surgical solutions. With a commitment to advancing the fields of laser and light-based technologies, Cynosure develops and manufactures a range of products that enhance patient care and outcomes in dermatology, plastic surgery, and medical aesthetics. The company actively engages in clinical trials to evaluate the safety and efficacy of its devices, ensuring compliance with regulatory standards and fostering scientific research. Cynosure's dedication to innovation and quality positions it at the forefront of the aesthetic medical industry, providing practitioners with cutting-edge tools to meet the evolving needs of their patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Westford, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported